When should you look at trials?

The timing myth

A lot of people picture a clinical trial as a final chapter — something you reach for only after every standard treatment has been tried. So they wait. They finish one treatment, then another, and only ask about trials when the usual options are gone.

That instinct is understandable. It is also the single most common way people miss out.

The truth is the opposite: the earlier you consider a trial, the more choices you tend to have.

Why waiting can close doors

Every trial has its own rules about who can join, and some of those rules are about your treatment history.

Certain trials are open only to people who have not had a particular therapy yet — or who have not had any treatment at all. Researchers set it up this way so they can measure clearly how a new approach works from the start. It is good science, but it has a real effect on you: if you have already had that treatment, you may no longer qualify.

So the sequence matters. A trial that would have been a great fit at diagnosis might be off the table a few months later, simply because of the order in which things happened.

Every decision point is a good moment

You do not need to ask about trials only once. Think of it as a question worth revisiting at each fork in the road:

• At diagnosis, before you choose a first treatment.
• When a treatment plan changes, or a new decision comes up.
• If a treatment stops working and you are weighing what’s next.
• After treatment, if you are looking at ways to lower the chance of recurrence.

At each of these points, a quick question — “Are there any trials I should consider right now?” — keeps you informed. Your care team can help you match the timing to what is actually available.

Gathering the details of your diagnosis early also makes this easier. Knowing your exact cancer type, stage, and any test results lets you and your team check trials quickly whenever a decision comes up. We walk through this in eligibility basics.

Early asking, open options

Asking early does not mean joining early. You might explore trials at diagnosis and decide standard treatment is the right first step — and that is a perfectly good outcome. The goal is not to rush into a trial. The goal is to make sure a trial is never quietly ruled out just because no one brought it up in time.

The earlier the question is on the table, the more freedom you have to choose. That is why “when should I look?” almost always has the same answer: now, and again at every turn.